Search

Transplantation has become a valid therapeutic option for an increasing number of patients with end-stage organ disease. The emergence of SARS-CoV-2 coronavirus infection and associated disease (COVID-19) has alarmed the transplant community, since recommendations for adequate follow-up of organ transplant recipients during the acute phase of a pandemic are limited. Furthermore, treatment options against COVID-19 disease and adequate adjustment of immunosuppression in at risk patients remain a concern. This review summarizes current knowledge on the incidence and clinical course of SARS-CoV-2 infection in patients with solid organ transplantation. It also discusses therapeutic strategies and provides general recommendations on how to proceed with transplantation programs in a time when health care resources may become scarce., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

Renal transplantation is the first-line therapy for eligible patients with end-stage kidney disease. However, approximately 20 % of cadaveric graft recipients need to start dialysis at 5 years. The transition period between transplantation and dialysis is at high risk of complications, but data exploring this issue are scarce. In this retrospective study from dialysis centres of the Canton de Vaud, we analysed the clinical data and management of these patients at the beginning of dialysis after graft loss, and up to one year after dialysis start. Our data show that such patients suffer from a high rate of complications, such as urgent start of dialysis, hospitalizations, severe hypertension and depression. We suggest that clinical management in this period should be revisited., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.